Te Ahumairangi Investment Management Ltd Sells 8,180 Shares of Gilead Sciences, Inc. $GILD

Te Ahumairangi Investment Management Ltd lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 13.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 51,976 shares of the biopharmaceutical company’s stock after selling 8,180 shares during the period. Gilead Sciences makes up approximately 1.1% of Te Ahumairangi Investment Management Ltd’s holdings, making the stock its 25th largest position. Te Ahumairangi Investment Management Ltd’s holdings in Gilead Sciences were worth $6,380,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Ares Financial Consulting LLC bought a new stake in Gilead Sciences in the 4th quarter worth approximately $28,000. Financial Consulate Inc. grew its position in Gilead Sciences by 85.8% in the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 109 shares during the period. North Star Investment Management Corp. grew its position in Gilead Sciences by 54.8% in the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 86 shares during the period. BOCHK Asset Management Ltd bought a new stake in Gilead Sciences in the 4th quarter worth approximately $31,000. Finally, Godfrey Financial Associates Inc. bought a new stake in Gilead Sciences in the 4th quarter worth approximately $34,000. Institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on GILD. Cantor Fitzgerald reiterated an “overweight” rating on shares of Gilead Sciences in a research note on Tuesday. Truist Financial reissued a “buy” rating and issued a $157.00 price objective (up from $155.00) on shares of Gilead Sciences in a report on Friday, May 8th. Needham & Company LLC reissued a “buy” rating and issued a $170.00 price objective on shares of Gilead Sciences in a report on Monday, February 23rd. Argus raised their price objective on shares of Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Finally, Mizuho raised their price objective on shares of Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. Twenty-five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $156.93.

Gilead Sciences Trading Up 3.6%

Shares of GILD stock opened at $125.87 on Friday. Gilead Sciences, Inc. has a 1 year low of $104.46 and a 1 year high of $157.29. The firm has a fifty day moving average price of $133.46 and a 200-day moving average price of $134.34. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The company has a market cap of $156.28 billion, a price-to-earnings ratio of 17.15 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter in the previous year, the firm posted $1.81 EPS. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities analysts predict that Gilead Sciences, Inc. will post -0.79 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be paid a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Bernstein initiated/maintained a Buy view on Gilead, adding to the bullish analyst sentiment around the stock. Gilead Sciences (GILD) Gets a Buy from Bernstein
• Positive Sentiment: Gilead and Merck reported positive topline Phase 3 results for their once-weekly oral HIV regimen (islatravir + lenacapavir), which strengthens the company’s growth story and HIV franchise outlook. Is Gilead (GILD) One of the Top Large Cap Value Stocks to Buy Now?
• Positive Sentiment: Gilead’s HIV business continues to get attention for momentum from Biktarvy, Descovy, and Yeztugo, with late-stage pipeline progress supporting the long-term earnings outlook. Can Gilead Sciences HIV Franchise Drive Long-Term Growth?
• Positive Sentiment: Recent Phase 3 IDEAL study results for Livdelzi in primary biliary cholangitis also reinforced confidence in Gilead’s pipeline development. Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline Development
• Neutral Sentiment: Gilead was cited in broader articles about pharma/biotech M&A and healthcare investing, which may keep the stock on traders’ radar but does not directly change fundamentals. Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
• Neutral Sentiment: Unusually heavy call-option activity suggests traders are positioning for more upside, though it is not a fundamental development.
• Neutral Sentiment: Gilead Foundation’s ~$3 million HIV/AIDS education commitment is positive for brand and ESG perception, but the financial impact is likely limited. National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $132.27, for a total transaction of $396,810.00. Following the sale, the chief financial officer owned 173,191 shares in the company, valued at approximately $22,907,973.57. This trade represents a 1.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the sale, the chief executive officer owned 617,567 shares in the company, valued at approximately $81,185,357.82. The trade was a 2.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 68,000 shares of company stock worth $9,047,570. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.